SM
BMY.RT

SG3 Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

SG3 Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-80,000
Closed -$304K – 744
2020
Q1 		$304K Buy
+80,000
New +$264K 0.04% 217

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG3 Management's BMY.RT Position: Q2 2020 in Review

SG3 Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q2 2020, closing a stake of 80,000 shares — an estimated $304K sold.

SG3 Management first reported a position in BMY.RT in Q1 2020 and held it in 1 quarter. The position peaked at $304K in Q1 2020. 583 funds tracked by Wall St. Rank hold BMY.RT as of Q2 2020.

  • SG3 Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q2 2020 after selling out during the quarter.
  • SG3 Management sold 80,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q2 2020, an estimated $304K.
  • SG3 Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 1 quarter.
  • SG3 Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $304K in Q1 2020.
  • 583 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q2 2020.

Based on SG3 Management's 13F filing for Q2 2020, filed 14 Aug 2020.